These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 989966)

  • 21. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time.
    Groce JB; Gal P; Douglas JB; Steuterman MC
    Clin Pharm; 1987 Mar; 6(3):216-22. PubMed ID: 3665377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer].
    Li J; Cong YL; Tu GH; Yang L; Zhu BB; Jin L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1269-71. PubMed ID: 17686264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
    Hürzeler C; von Felten A
    Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of undiagnosed coagulopathies using routine rapid heparin neutralization.
    Burns ER; Lee V; Wenz B
    Clin Lab Sci; 1995; 8(2):113-6. PubMed ID: 10150468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
    Varah N; Smith J; Baugh RF
    Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control and complications of intermittent heparin therapy.
    Norman CS; Provan JL
    Surg Gynecol Obstet; 1977 Sep; 145(3):338-42. PubMed ID: 888052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation between plasma concentration of heparin and biological response determined by 2 APTT reagents of different sensitivities].
    Bassini E; Miceli M; Cini S; Francalanci R
    Quad Sclavo Diagn; 1986 Jun; 22(2):193-200. PubMed ID: 3823368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects.
    Gawoski JM; Arkin CF; Bovill T; Brandt J; Rock WA; Triplett DA
    Arch Pathol Lab Med; 1987 Sep; 111(9):785-90. PubMed ID: 3632297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
    Robert A
    Thromb Haemost; 1994 Feb; 71(2):220-4. PubMed ID: 8191402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies of phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin.
    Barrowcliffe TW; Gray E
    Thromb Haemost; 1981 Oct; 46(3):634-7. PubMed ID: 7314057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service.
    Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S
    Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant.
    Adcock DM; Marlar RA
    Arch Pathol Lab Med; 1992 Aug; 116(8):837-40. PubMed ID: 1497465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical value of a new method of therapeutic control of heparin].
    Pizzuto J; Garcia S; de la Paz Reyna M; Morales MR; Avilés A; Zavala B; Ponce L; Gaos C
    Arch Inst Cardiol Mex; 1978; 48(2):373-86. PubMed ID: 666447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development.
    Dudek MM; Harris LF; Killard AJ
    Int J Lab Hematol; 2011 Jun; 33(3):272-80. PubMed ID: 21118388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Theoretical basis and practical carrying out of an APTT control test for exact heparin monitoring (author's transl)].
    Vogel GE
    Med Klin; 1977 Feb; 72(6):207-11. PubMed ID: 840137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring of intraoperative heparinization in vascular surgery.
    Manny J; Romanoff H; Hyam E; Manny N
    Surgery; 1976 Nov; 80(5):641-3. PubMed ID: 982283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.